Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry

Hyeon-Gyu YI; Jin-Seok KIM; Cheolwon SUH; Won-Seog KIM; Jae-Yong KWAK; Jong-Seok LEE; Yang-Soo KIM; Young-Don JOO; Yoo-Hong MIN; Hong-Ghi LEE; Sung-Soo YOON; Jong-Ho WON; Seonyang PARK; Hugh-Chul KIM; Chul-Soo KIM.
Blood Research ; : 115-120, 2013.
Artículo en Inglés | WPRIM | ID: wpr-74589

Documentos relacionados

  1. On clinical trial fragility due to patients lost to follow up.
  2. Clinical outcomes after incomplete cycles of R-CHOP for diffuse large B-cell lymphoma: 10 years' real-world experience in a single institute.
  3. Lost but not missing: factors associated with loss of follow-up in a paediatric cardiology clinic.
  4. "Patient Lost to Follow-up": Opportunities and Challenges in Delivering Primary Care in Academic Medical Centers.
  5. Quality of Follow-up: Systematic Review of the Research in Bariatric Surgery.
  6. A scoping review on the factors associated with the lost to follow-up (LTFU) amongst patients with chronic disease in ambulatory care of high-income countries (HIC).
  7. Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin's lymphoma.
  8. The Blight of the Type II Error: When No Difference Does Not Mean No Difference.
  9. An empirical analysis of dealing with patients who are lost to follow-up when developing prognostic models using a cohort design.
  10. Secondary central nervous system involvement in patients with diffuse large B-cell lymphoma treated with rituximab combined CHOP therapy - a supplementary analysis of JCOG0601.